Regional Investment Agency Targets Life Sciences Startups to Bridge Critical Funding Gap
Amsterdam, Sunday, 24 May 2026.
ROM InWest addresses a major challenge plaguing healthcare innovation: the notorious ‘Valley of Death’ period where medical technology companies struggle to secure funding while pursuing expensive regulatory certifications. The agency’s strategic focus on biotech, medical devices, and digital health startups fills a crucial gap that traditional investors avoid, helping companies like HeartEye advance their wireless ECG technology toward market approval. This initiative positions Noord-Holland to capitalize on breakthrough medical innovations while supporting companies through the most vulnerable phase of their development journey.
Three-Pronged Investment Strategy Targets Healthcare Innovation
ROM InWest’s investment approach centers on three distinct domains within the life sciences sector: digital health solutions, innovative medical equipment (MedTech), and biotechnology developments [1]. This comprehensive strategy reflects the agency’s understanding that healthcare innovation requires diverse technological approaches to address complex medical challenges. The investment focus aligns with the Netherlands’ established position as a leading hub for life sciences innovation, particularly leveraging Noord-Holland’s existing research institutions and healthcare infrastructure [GPT]. According to Sara, a representative from ROM InWest, the challenge for many life sciences startups extends beyond typical funding difficulties: “Voor veel LSH‑startups is het extreem lastig om de juiste financiering te vinden om te kunnen groeien” [1]. The agency specifically targets early-stage companies that traditional investors consider too risky, bridging the gap until conventional funding sources become viable.
Medical Device Success Stories Demonstrate Investment Impact
HeartEye exemplifies ROM InWest’s targeted approach to medical technology funding, having received investment to advance its wireless 12-channel ECG recorder toward CE certification [1]. The company represents the type of hardware-focused medical device startup that faces particularly steep funding challenges due to regulatory requirements. As Sara explains, “Deze ondernemingen maken hardware en hebben daarvoor een strikte, zorgspecifieke CE‑certificering nodig…Om die te verkrijgen moet het product uitontwikkeld zijn en dat kost veel geld” [1]. Another portfolio company, Amplio Pharma, has developed NovoBioJect, an innovation that improves the effectiveness of methotrexate, a rheumatoid arthritis drug, while reducing side effects and delaying the need for expensive biological treatments [1]. This approach of enhancing existing medications demonstrates how ROM InWest supports both breakthrough technologies and incremental improvements that can deliver significant patient benefits and healthcare cost savings.
Artificial Intelligence Transforms Healthcare Delivery
ROM InWest’s recent investment in Healthplus.ai illustrates the agency’s commitment to digital health solutions that leverage artificial intelligence to improve patient outcomes [1]. The company has developed an AI system specifically designed for hospitals to predict postoperative complications for individual patients, representing a significant advancement in personalized healthcare risk assessment [1]. However, the adoption of AI models in healthcare faces substantial implementation challenges due to complex hospital IT landscapes and lengthy decision-making processes, which can hinder companies like Healthplus.ai from scaling their solutions effectively [1]. These technological barriers highlight why traditional investors often avoid healthcare AI startups, creating the funding gap that ROM InWest seeks to fill. The agency’s willingness to invest during these early adoption phases positions it to support companies through the critical period before widespread market acceptance occurs.
Economic Impact and Healthcare Cost Management
The financial implications of ROM InWest’s life sciences investments extend beyond individual company success to broader healthcare system efficiency. Treatment of infections alone costs the average hospital €35 million annually [1], illustrating the substantial economic burden that innovative medical technologies could help reduce. Sara emphasizes the agency’s strategic positioning in the funding ecosystem: “Bij ROM InWest signaleren we deze problemen en kiezen we er bewust voor om wél te investeren in de vroege fase van deze ondernemingen in LSH. Door als brug te fungeren naar het moment waarop traditionele geldverstrekkers kunnen instappen of er voldoende omzet uit commerciële verkoop is, vergroten we de kans dat impactvolle innovaties daadwerkelijk de zorgpraktijk bereiken” [1]. This approach demonstrates how regional development agencies can play a crucial role in healthcare innovation by accepting risks that private investors typically avoid. The strategy not only supports individual companies but also strengthens Noord-Holland’s position in the competitive global healthcare technology market, potentially attracting additional investment and talent to the region as these early-stage companies mature and demonstrate commercial viability.